iOnctura to present research on roginolisib and IOA-359 at ASH finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
FDA Approval Insights: Glofitamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
Administration of glofitamab after pretreatment with obinutuzumab provided encouraging antitumor activity with high and durable complete response rates and a manageable safety profile in heavily pretreated patients with Richter syndrome.
Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months Safety profile substantially consistent with prior findings